<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202605</url>
  </required_header>
  <id_info>
    <org_study_id>SPD465-203</org_study_id>
    <nct_id>NCT00202605</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SPD465 in Adults With ADHD</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate how safe and how well SPD465 works compared to
      placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration
      of clinical benefit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PERMP (Permanent Product Measure of Performance) at 7 time points</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Segment Rating System (ADHD-RS[TSRS])</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject self report (ADHD-SRS) of ADHD</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Pittsburgh Sleep Quality Index (PSQI)</measure>
  </secondary_outcome>
  <enrollment>72</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of ADHD using DSM-IV-TR criteria (at least 6 of the 9 subtype
             criteria met)

          -  Baseline ADHD-RS-IV score =&gt;24

          -  IQ score of =&gt; 80 (using Kaufman Brief Intelligence Test)

        Exclusion Criteria:

          -  BMI &lt; 18.5 or &gt; 30 kg/m2

          -  Diagnosis of Post Traumatic Stress Disorder, psychosis, bipolar illness, severe
             obsessive compulsive disorder, severe depressive or severe anxiety disorder

          -  History of seizure disorder or a lifetime history of any seizures (other than
             infantile febrile seizures), any tic disorder, or a current diagnosis and/or family
             history of Tourette's Disorder

          -  History of uncontrolled hypertension or currently hypertensive

          -  Subjects who have taken atomoxetine (STRATTERA) within 30 days prior to screening

          -  Current (or history within the last 12 months) of drug dependence or substance abuse
             disorder according to DSM-IV-TR criteria (excluding nicotine)

          -  Female subject is pregnant or lactating, less than 3 months post partum
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Study Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Child Development Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayou City Research, Ltd.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>November 2, 2007</last_update_submitted>
  <last_update_submitted_qc>November 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

